Pfizer inks deal with Vivet Therapeutics in liver disorder

Pfizer (NYSE:PFE) and Vivet Therapeutics, a privately held gene therapy biotech company have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and life-threatening liver disorder.

Terms of the agreement were not disclosed. The trial is expected to commence in early 2021.

The Phase 1/2 clinical supply for VTX-801 will be manufactured in Pfizer’s facility in Chapel Hill, North Carolina.

In March 2019, Pfizer acquired 15% ownership stake in Vivet and collaborated for the development of VTX-801.

Share: